Cardinal Health, Inc. (BMV:CAH)

Mexico flag Mexico · Delayed Price · Currency is MXN
3,995.00
0.00 (0.00%)
Last updated: Jul 17, 2026, 8:30 AM CST
Market Cap925.31B +29.9%
Revenue (ttm)4.52T +12.8%
Net Income28.03B -0.1%
EPS117.85 +2.5%
Shares Out n/a
PE Ratio33.01
Forward PE19.44
Dividend36.77 (0.92%)
Ex-Dividend DateJul 1, 2026
Volumen/a
Open3,995.00
Previous Close3,995.00
Day's Range3,995.00 - 3,995.00
52-Week Range2,686.00 - 4,028.45
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2026

About Cardinal Health

Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products.... [Read more]

Industry Drugs, Drug Proprietaries, and Druggists' Sundries
Founded 1979
Employees 55,392
Stock Exchange Mexican Stock Exchange
Ticker Symbol CAH

Financial Performance

In fiscal year 2025, Cardinal Health's revenue was $222.58 billion, a decrease of -1.87% compared to the previous year's $226.83 billion. Earnings were $1.56 billion, an increase of 83.22%.

Financial numbers in USD Financial Statements

News

Cardinal Health to buy AdaptHealth diabetes unit, Strive Medical for $360 million

Cardinal Health said on Monday it has agreed to buy AdaptHealth's diabetes health business and ​medical supply provider Strive Medical in separate deals ‌for about $360 million in total, expanding its...

1 day ago - Reuters

Cardinal to acquire Diabetes business of AdaptHealth, Strive Medical for $360M

Cardinal Health (CAH) announced it has entered into two definitive agreements. Cardinal Health will acquire the Diabetes Health business of AdaptHealth (AHCO), and, in its entirety, Strive Medical, a ...

1 day ago - TheFly

Cardinal Health expands home care business with two tuck-in acquisitions

DUBLIN, Ohio, July 20, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today it has entered into two definitive agreements that accelerate its at-Home Solutions' growth strategy. Cardinal H...

1 day ago - PRNewsWire

AdaptHealth to divest diabetes health business to Cardinal Health for $235M

AdaptHealth Corp. (AHCO) that it is divesting its Diabetes Health business to Cardinal Health (CAH). Under the terms of an agreement signed July 19, 2026, Cardinal Health will acquire AdaptHealth’s…

1 day ago - TheFly

Cardinal Health price target raised to $274 from $260 at UBS

UBS raised the firm’s price target on Cardinal Health (CAH) to $274 from $260 and keeps a Buy rating on the shares.

1 day ago - TheFly

Cardinal Health price target raised to $275 from $255 at TD Cowen

TD Cowen raised the firm’s price target on Cardinal Health (CAH) to $275 from $255 and keeps a Buy rating on the shares. The firm updated its model ahead of…

12 days ago - TheFly

Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11

DUBLIN, Ohio, July 9, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2026 on August 11, prior to the opening of tra...

12 days ago - PRNewsWire

Cardinal Health price target raised to $260 from $240 at BofA

BofA raised the firm’s price target on Cardinal Health (CAH) to $260 from $240 and keeps a Buy rating on the shares, citing relative upside to consensus estimates and strong…

19 days ago - TheFly

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

4 weeks ago - Forbes

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deo...

5 weeks ago - PRNewsWire

Cardinal Health Transcript: Bank of America Global Healthcare Conference 2026

Strong Q3 profit growth and raised guidance reflect robust demand and operational execution across all segments. Strategic M&A in GI and urology, investments in innovation, and disciplined capital allocation support long-term growth and resilience.

2 months ago - Transcripts

Cardinal Health Board of Directors Approves Quarterly Dividend

DUBLIN, Ohio, May 5, 2026  /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Compa...

2 months ago - PRNewsWire

Cardinal Health price target lowered to $215 from $243 at JPMorgan

JPMorgan analyst Lisa Gill lowered the firm’s price target on Cardinal Health (CAH) to $215 from $243 and keeps a Neutral rating on the shares.

2 months ago - TheFly

Cardinal Health price target lowered to $248 from $257 at Baird

Baird lowered the firm’s price target on Cardinal Health (CAH) to $248 from $257 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results…

2 months ago - TheFly

Cardinal Health price target raised to $255 from $251 at TD Cowen

TD Cowen raised the firm’s price target on Cardinal Health (CAH) to $255 from $251 and keeps a Buy rating on the shares. The firm updated its model following quarterly…

2 months ago - TheFly

Cardinal Health price target lowered to $245 from $249 at Citi

Citi analyst Daniel Grosslight lowered the firm’s price target on Cardinal Health (CAH) to $245 from $249 and keeps a Buy rating on the shares.

2 months ago - TheFly

Cardinal Health price target lowered to $240 from $260 at BofA

BofA lowered the firm’s price target on Cardinal Health (CAH) to $240 from $260 to reflect lower peer multiples, while keeping a Buy rating on the shares. The firm notes…

2 months ago - TheFly

Cardinal Health raises FY26 EPS view to $10.70-$10.80 from $10.15-$10.35

Consensus $10.31. Raises FY26 adjusted free cash flow view to $3.3B-$3.7B from $3B-$3.5B. Lowers FY26 tax rate view to 19% from 21%-23%.

2 months ago - TheFly

Cardinal Health Earnings Call Transcript: Q3 2026

Q3 saw double-digit revenue and profit growth, led by specialty and pharma, with robust results in other growth businesses. Guidance for EPS and free cash flow was raised, reflecting operational strength, tax benefits, and successful M&A integration.

2 months ago - Transcripts

Cardinal Health Earnings release: Q3 2026

Cardinal Health released its Q3 2026 earnings on April 30, 2026, summarizing the period's financial results.

2 months ago - Filings

Cardinal Health Slides: Q3 2026

Cardinal Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 30, 2026.

2 months ago - Filings

Cardinal Health Quarterly report: Q3 2026

Cardinal Health has published its Q3 2026 quarterly earnings report on April 30, 2026.

2 months ago - Filings

Cardinal Health Rises. A Guidance Hike Powers the Stock Past These Weak Points.

Cardinal Health raises its fiscal-year adjusted earnings guidance for the second time this year, helping investors look past mixed quarterly performance.

2 months ago - Barrons

Cardinal Health Lifts Outlook Again as Revenue Rises

Cardinal Health once again raised its full-year outlook after logging higher-than-expected adjusted earnings in the third quarter.

2 months ago - WSJ

Cardinal Health lifts annual profit forecast on strong demand for specialty drugs

Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on ​strong demand for costly specialty medicines and branded ‌drugs at its pharmaceuticals unit.

2 months ago - Reuters